Study summary
BTK inhibitors shrank CNS lymphoma in about three-quarters of patients
73%pooled response rate
What was tested
A pooled analysis of 40 studies of BTK inhibitors (ibrutinib, zanubrutinib, orelabrutinib and others), alone or with chemotherapy, for primary and secondary CNS lymphoma.
What they found
- Pooled response rate was 73%, with complete responses in 49%.
- Combinations with chemotherapy did better (79%) than BTK inhibitors alone (60%).
What it means
Supports adding BTK inhibitors to first-line chemotherapy, now being tested in randomized trials.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.